Dergiler / Organic Communications / 2022 / Cilt: 15 - Sayı: 2

Discovering the potential of natural remedies in the post COVID-19 complications based on in silico techniques

Sayfa
81–95
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Allicin, Berberine, Epigallocatechin, Rosmarinic acid and Withaferin-A were docked against ACE (PDB ID: 1O8A), IL-6 (PDB ID: 1ALU), NADPH Oxidase (PDB ID: 2CDU) and TNF- α (PDB ID: 2AZ5) using Autodock.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The first incidence of corona virus was reported in China in December of 2019, and the virus quickly spread over the world, eventually being designated a pandemic in March of 2020.
📊
Temel Bulgular & Veri:Virus has claimed the lives of 5,298,933 people through December 2021.
💡
Sonuç & Katkı:Allicin, Berberine, Epigallocatechin, Rosmarinic acid and Withaferin-A were docked against ACE (PDB ID: 1O8A), IL-6 (PDB ID: 1ALU), NADPH Oxidase (PDB ID: 2CDU) and TNF- α (PDB ID: 2AZ5) using Autodock.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

The first incidence of corona virus was reported in China in December of 2019, and the virus quickly spread over the world, eventually being designated a pandemic in March of 2020. It has had a disastrous impact o the global healthcare system. Virus has claimed the lives of 5,298,933 people through December 2021. As a result of the pandemic, there was a boost of research into diagnostic and therapeutic methods to infection. Gradually, the world has discovered new vaccine candidates and medicinal repurposing strategies that have a significant influence on mortality, by which there has been a drop-in death rates over the world since July, 2021. Many patients, particularly those who have been hospitalized due to a viral infection, experience complications beyond discharge that have a significant influence on their lives. Post COVID-19 complications are problems that last longer than 3-4 weeks following a viral infection. There is currently no specific treatment accessible for post COVID-19 problems because whatever medications are available or repurposed are limited to disease prophylaxis and therapeutics. As a result, we're looking for a remedy employing natural substances using the In-Silico technique (molecular docking) and recent research from reputable journals. Allicin, Berberine, Epigallocatechin, Rosmarinic acid and Withaferin-A were docked against ACE (PDB ID: 1O8A), IL-6 (PDB ID: 1ALU), NADPH Oxidase (PDB ID: 2CDU) and TNF- α (PDB ID: 2AZ5) using Autodock.

🔖

Bu Makaleye Atıf Yap

PATEL, A., PATAL, A., SHAH, R., ZİNZUVADİA, D., MAHANT, S. (2022). Discovering the potential of natural remedies in the post COVID-19 complications based on in silico techniques. Organic Communications, Cilt: 15 - Sayı: 2, 81–95. https://ajindex.com/articles/419569

Kaynakça (10)

  1. Costela-Ruiz, V.J.; Illescas-Montes, R.; Puerta-Puerta, J.M.; Ruiz, C.; Melguizo-Rodríguez, L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020, 54, 62-75
  2. Habas, K.; Nganwuchu, C.; Shahzad, F.; Gopalan, R., Haque, M.; Rahman, S.; Mjumder, A.A.; Nasim, T. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev. Anti-Infect. Therap. 2020, 18 (12), 201- 1211
  3. Soy, M.; Keser, G.; Atagündüz, P.; Tabak, F.; Atagündüz, I.; Kayhan, S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin. Rheumatol. 2020, 39 (7), 2085- 2094
  4. Umakanthan, S.; Sahu, P.; Ranade, A. V.; Bukelo, M.M.; Sushil, R.; Abrahao-Machado, L.F.; Dahal, S.; Kumar, H.; Kv, D. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19).Postgrad. Medical J. 2020, 96 (1142), 753-758
  5. Cascella, M.; Rajnik, M.; Aleem, A.; Dulebohn, S.C.; Di Napoli, R. Features, Eevaluation, and treatment of coronavirus-StatPearls-NCBIBookshelf. Published online 2021. https://www.ncbi.nlm.nih.gov/ books/- NBK554776/ [6] Chen, J.;0 Wang, R.; Gilby, N.B.; Wei, G.W. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. Published online December 1, 2021.
  6. Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; Korompoki, E.; Ftiou, M.; Tzanninis, I.G.; Psaltopoulou, T.; Kastritis, E.; Terpos, E.; Dimopılous, M.A. Emerging treatment strategies for COVID-19 infection. Clin. Experiment. Medicin. 2021, 21(2),167-179
  7. Chakraborty, S.; Mallajosyula, V.; Tato, C.M.; Tan, G.S.; Wang, T.T. SARS-CoV-2 vaccines in advanced clinical trials: where do we stand? Adv. Drug Deliv. Rev. 2021, 172, 314-338
  8. Bakhiet, M.; Taurin S. SARS-CoV-2: Targeted managements and vaccine development. Cytokine Growth Factor Rev. 2021, 58,16-29
  9. Francis, A.I.; Ghany, S.; Gilkes, T.; Umakanthan, S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad. Medical J. Published online 2021, 140654.doi:10.1136/ postgradmedj- 2021-140654 [11] Agarwal, S.; Saha, S.; Darbar, S. COVID19 Vaccine: COVAXIN ®-India’s first indigenous effective weapon to fight against Coronavirus (A Review). Parana J. Sci. Education. 2021, 7(3), 1-9
  10. Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S. et al. Post-acute COVID-19 syndrome. Nature Medicin.